Literature DB >> 9874918

Is there a role for continuation phase cognitive therapy for depressed outpatients?

R B Jarrett1, M R Basco, R Risser, J Ramanan, M Marwill, D Kraft, A J Rush.   

Abstract

Two pilot studies evaluated the rate of relapse or recurrence (i.e., major depressive disorder) after cognitive therapy (CT). Two sequential cohorts included outpatients who responded to acute phase CT (A-CT) and who agreed to monthly, treatment-free follow-up. In Study 1, the Kaplan-Meier technique estimated relapse and recurrence rates of 40% at 6 months, 45% at 8 months, 50% at 12 months, 67% at 18 months, and 74% at 24 months. In Study 2, responders to A-CT received 8 months (10 sessions) of continuation phase CT (C-CT). In Study 2, relapse or recurrence was 20% at 6 and 8 months, 27% at 12 months, and 36% at 18 and 24 months after A-CT. An exploratory log-rank test showed that relapse or recurrence-free survival was greater in Study 2 than in Study 1. If replicated, this result suggests that C-CT can reduce depressive relapse or recurrence. Alternative explanations are presented.

Entities:  

Mesh:

Year:  1998        PMID: 9874918     DOI: 10.1037//0022-006x.66.6.1036

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  18 in total

1.  Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.

Authors:  Robin B Jarrett; Michael E Thase
Journal:  Contemp Clin Trials       Date:  2010-05-06       Impact factor: 2.226

2.  Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults.

Authors:  Katja Machmutow; Ramona Meister; Alessa Jansen; Levente Kriston; Birgit Watzke; Martin Christian Härter; Sarah Liebherz
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

3.  Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.

Authors:  Robin B Jarrett; Abu Minhajuddin; Howard Gershenfeld; Edward S Friedman; Michael E Thase
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

4.  Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial.

Authors:  R B Jarrett; D Kraft; J Doyle; B M Foster; G G Eaves; P C Silver
Journal:  Arch Gen Psychiatry       Date:  2001-04

5.  Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  J Consult Clin Psychol       Date:  2014-07-21

6.  Explicating an evidence-based, theoretically informed, mobile technology-based system to improve outcomes for people in recovery for alcohol dependence.

Authors:  David H Gustafson; Bret R Shaw; Andrew Isham; Timothy Baker; Michael G Boyle; Michael Levy
Journal:  Subst Use Misuse       Date:  2011       Impact factor: 2.164

7.  Is liability to recurrent major depressive disorder present before first episode onset in adolescence or acquired after the initial episode?

Authors:  Jeremy W Pettit; Chelsey Hartley; Peter M Lewinsohn; John R Seeley; Daniel N Klein
Journal:  J Abnorm Psychol       Date:  2013-05

8.  How much cognitive therapy, for which patients, will prevent depressive relapse?

Authors:  Robin B Jarrett; Jeffrey R Vittengl; Lee Anna Clark
Journal:  J Affect Disord       Date:  2008-03-21       Impact factor: 4.839

9.  Improvement in social-interpersonal functioning after cognitive therapy for recurrent depression.

Authors:  J R Vittengl; L A Clark; R B Jarrett
Journal:  Psychol Med       Date:  2004-05       Impact factor: 7.723

10.  Changes in cognitive content during and following cognitive therapy for recurrent depression: substantial and enduring, but not predictive of change in depressive symptoms.

Authors:  Robin B Jarrett; Jeffrey R Vittengl; Kimberly Doyle; Lee Anna Clark
Journal:  J Consult Clin Psychol       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.